Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases

68Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials.

References Powered by Scopus

Caspases: Key players in programmed cell death

453Citations
N/AReaders
Get full text

Regulation of p53 function and stability by phosphorylation

392Citations
N/AReaders
Get full text

Cladribine (2-chlorodeoxyadenosine)

352Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Current and emerging therapies for acute myeloid leukemia

134Citations
N/AReaders
Get full text

Synthesis of Best-Seller Drugs

111Citations
N/AReaders
Get full text

Older and new purine nucleoside analogs for patients with acute leukemias

95Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Robak, T., Korycka, A., Ewa, L. M., & Robak, P. (2009, March). Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules. https://doi.org/10.3390/molecules14031183

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 28

62%

Researcher 9

20%

Professor / Associate Prof. 5

11%

Lecturer / Post doc 3

7%

Readers' Discipline

Tooltip

Chemistry 15

34%

Medicine and Dentistry 15

34%

Agricultural and Biological Sciences 9

20%

Pharmacology, Toxicology and Pharmaceut... 5

11%

Save time finding and organizing research with Mendeley

Sign up for free